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Abstract 26 
Emerging evidence from human intervention trials indicates health benefits of consuming 27 
blackcurrant fruit, including improvements to cognitive performance, modulation of blood flow, 28 
regulation of blood glucose and inhibition of enzymes underpinning normal cognitive function. Of 29 
particular relevance is our previous demonstration of monoamine oxidase (MAO)-A and B inhibition 30 
after the consumption of a New Zealand ‘Blackadder’ blackcurrant juice in humans. 31 
The current study uses a double-blind, placebo-controlled, randomised cross- over design to assess 32 
the pharmacodynamics of the effects on platelet MAO-B inhibition and associated substrates, plasma 33 
prolactin levels and blood glucose levels after consumption of a single serve of ‘Blackadder’ 34 
blackcurrant juice standardised to 500mg polyphenols. Eight healthy male (20-–35 years) participants 35 
completed the trial. Measurements were obtained at baseline 15, 30, 45, 60, 100, 120, 150, 180, 240 36 
mins and 24 hours post dose. 37 
A fast, absolute and reversible inhibition of blood platelet MAO-B (P<0.001) and a significant but 38 
delayed reduction in plasma prolactin (P<0.001) were observed following the consumption of 39 
‘Blackadder’ blackcurrant juice when compared to a placebo control. No interpretable changes in 40 
substrates of MAO or associated metabolites were seen.  41 
These data provide a clear time course of the reversible inhibition of MAO-B after the single 42 
consumption of a of New Zealand ‘Blackadder’ blackcurrant juice standardised at 500mg of 43 
polyphenols and, therefore, provide a therapeutic window on which to base future nutritional 44 
interventions.   45 
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Introduction 46 
Blackcurrants (Ribes nigrum) are a berry fruit high in polyphenols when compared to other similar 47 
berries [1], with 3-O-glucosides and the 3-O-rutinosides of anthocyanins delphinidin and cyanidin 48 
representing the major phenolic constituents [2]. Other phenolic structures, such as phenolic acids 49 
are also present in smaller quantities [3]. Emerging evidence supports health benefits of consuming 50 
blackcurrant fruit, including modulation of blood flow [4, 5] and brain wave spectral activity [6]; 51 
improvements to cognitive performance [7], and inhibition of monoamine oxidase (MAO) enzymes in 52 
humans [7]. 53 
Monoamine oxidase enzyme isoforms -A and -B are present in the periphery and the central 54 
nervous system and play a major role in the metabolism of both dietary and endogenous monoamines 55 
[8]. MAO-A preferentially catalyses the oxidation of serotonin; MAO-B is more active towards β-56 
phenylethylamine and benzylamine; whereas dopamine, adrenaline, noradrenaline tryptamine and 57 
tyramine are oxidised by both isoforms [9]. Inhibition of MAO therefore results in an increased 58 
concentration of monoamine neurotransmitters and, in the case of MAO-B inhibition, is well 59 
documented as a therapeutic treatment for Parkinsonian symptoms  [10]. Monoamine inhibition can 60 
be reversible or irreversible and can either act non-selectively, affecting both isoforms, or selectively, 61 
affecting only one isoform. For example, phenelzine is an irreversible, non-selective MAO inhibitor, 62 
which inhibits both MAO-A and B for up to three weeks [11]; in contrast, toloxatone, a reversible 63 
inhibitor of MAO-A (RIMA), inhibits MAO-A for only six hours before activity returns to baseline values 64 
[12]. This selective inhibition is preferable as the inhibition of both MAO isoforms can in some 65 
instances prevent the degradation of dietary amines in the digestive tract and if this continues for 66 
prolonged periods tyramine can accumulate to dangerous levels, potentiating a hypertensive crisis. It 67 
is therefore important to identify reversible and/or selective MAO inhibitors.  68 
Our previous demonstration of MAO inhibition following blackcurrant consumption, outlined 69 
the efficacy of a cold-pressed blackcurrant juice (‘Blackadder’ cultivar) in inhibiting both MAO isoforms 70 
in the periphery. These findings were coupled with  a non-significant reduction in plasma prolactin, 71 
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potentially indicating modulations in circulating dopamine levels [7]. This inhibition, observed in 72 
healthy young adults measured at ~2 hours post consumption, was particularly striking for MAO-B 73 
indicating an almost complete inhibition (96 %). It is therefore of great importance to ascertain the 74 
pharmacodynamics of this action in order to establish if it is safe, reversible and to determine the 75 
optimal timing of dosing. A mild increase in blood glucose was also observed when measured at 1 and 76 
2.5 hours post consumption of ‘Blackadder’ blackcurrant when compared to control. This increase is 77 
contrary to expectation based upon a previous observation of decreased post-prandial peak blood 78 
glucose levels following apple juice [13]. It is theorised that attenuation of glucose absorption is due 79 
to inhibition of sodium-glucose transport proteins in the gut lumen after exposure to phenolic acids 80 
[14]. Therefore, the previously observed higher blood glucose readings may have been due to a 81 
slowing of glucose uptake following consumption of ‘Blackadder’ blackcurrant, rather than an overall 82 
increase in blood glucose. It is therefore important that the current study investigates more frequent 83 
time points to establish a pattern of glucose modulation after consumption of ‘Blackadder’ juice. 84 
 The current study will assess the pharmacodynamics of peripheral MAO-B inhibition, 85 
associated catecholamine and prolactin levels, and venous blood glucose profile following 86 
consumption of ‘Blackadder’ blackcurrant. The trial will utilise the 500 mg/60 kg of body weight dose 87 
of cold pressed ‘Blackadder’ juice (equivalent to ~100 g of fresh fruit) which was shown to have MAO 88 
inhibitory effects in our previous report and effects will be measured in a cohort of healthy male adult 89 
volunteers. 90 
 91 
 92 
 93 
 94 
 95 
 96 
 97 
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Materials and methods 99 
Design 100 
The study followed a double-blind, counterbalanced, placebo-controlled, repeated measures design. 101 
Participants were randomly allocated to treatment orders as selected through a Williams Latin Square 102 
[15]. 103 
Participants 104 
Eight healthy male adults participated in the study and provided all samples at all time points. 105 
Participant characteristics can be found in Table 1. Women were omitted due to changes in circulating 106 
prolactin levels during the menstrual cycle [16]. Power analysis was determined using post dose 107 
monoamine-B activity levels after supplementation with a similar blackcurrant juice  as described in 108 
our previous paper [7]. A two tailed A priori power analysis using G-power [17] was used to indicate 109 
the samples size needed to achieve an alpha error probability of 0.01. The power analysis indicated 110 
that a sample size of 7 would be needed to achieve a power of 0.99. 111 
TABLE 1 NEAR HERE 112 
Participants were recruited using opportunity sampling. Participants received £70 to recompense 113 
them for any expense they may have incurred to participate in the trial. Before participants were 114 
enrolled in the study they attended a 20 minute screening session. During this screening session 115 
participants gave their informed consent to participate in the study and were screened for any 116 
contraindications to the study with the use of an exclusion questionnaire. Exclusion criteria included: 117 
Risk or diagnosis of blood-borne disease, diagnosed history of any psychiatric disorder, aged under 18 118 
or over 35 years, BMI above 30 kg/m2 or below 17 kg/m2, diagnosis of diabetes or current use of 119 
prescription, over-the-counter or recreational drugs. Recruitment ceased when eight full sets of data 120 
were successfully attained. 121 
The study received ethical approval (RE20-10-11208) and was conducted according to the Declaration 122 
of Helsinki (1964). 123 
 124 
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Treatments 125 
The 'Blackadder' juice was assessed for phytochemical profile using the method described by Schrage 126 
et al., [18].  Participants received two drinks with at least one week washout between treatments. 127 
These drinks contained either 0 mg of polyphenols (control) or ~500 mg/ polyphenols per 60 kg of 128 
body weight in the form of a cold-pressed New Zealand blackcurrant juice (‘Blackadder’ cultivar). Dose 129 
ranges of individual phenolic constituents can be found in Table 2 and total dose ranges of phenolic 130 
groups can be found in Table 3. 131 
Drinks were matched for sugars and taste. In each case, drinks comprised of 3.44 g of glucose, 4.63 g 132 
of fructose, 0.8 g of sucrose, 6 g of SplendaTM and 50 ml of blackcurrant flavouring (Schweppes 133 
blackcurrant cordial). The total volume of the drink was made up to 200 ml with water and served 134 
chilled in an opaque brown bottle by an independent third party. All quantities discussed are based 135 
on a 60 kg person, drink quantities were calculated per kilo of body weight. A breakdown of 136 
anthocyanins and other phenolics in the study drinks can be seen in Tables 2 and 3. 137 
TABLE 2 NEAR HERE 138 
TABLE 3 NEAR HERE 139 
Blood collection and storage 140 
Blood was collected from an inlaying cannula in the left median cubital vein (21 Gauge, Becton, 141 
Dickinson and Company, UK). Venous blood samples (15 ml) were collected at baseline and 10 further 142 
time points post consumption of study treatments. Samples were collected in either BD Vacutainers© 143 
(Becton, Dickinson and company) or with 20 µl end-to-end capillary (EKF Diagnostics). Vacutainer 144 
receptacles were treated with anticoagulants, one with lithium heparin (LH) and one with 145 
ethylenediaminetetraacetic acid (EDTA). Whole blood samples treated with LH were immediately 146 
centrifuged (4 °C, 5000 rpm, 10 minutes) (Hitachi Himac preparative ultracentrifuge model CP100MX). 147 
Plasma was then extracted and aliquoted into 1.5 ml Eppendorf© tubes and stored at -80 °C until 148 
analysis. Whole blood samples treated with EDTA were used to isolate platelet cells prepared for 149 
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storage using the methods as described by Snell et al., [19]. Prepared platelet pellets were stored at -150 
80 °C until MAO-B activity analysis was performed. 151 
MAO analysis 152 
Isolated platelet pellets were prepared using methods described by Watson et al., [7] and analysed 153 
for MAO-B activity using the Amplex® Red Monoamine Oxidase-B Assay Kit (A12214 Invitrogen), as per 154 
manufacturer’s instructions. 155 
Circulating 3,4-dihydroxyphenylglycol (DHPG) was used as a proxy for MAO-A activity [20]. This 156 
method has been used in many pharmacological MAO inhibitor studies [20, 21]. 157 
 158 
Prolactin analysis 159 
Prolactin analysis was conducted by Diagnostic Medlab, Auckland, New Zealand in 300 µl of LH treated 160 
blood plasma. 161 
Catecholamine Analysis 162 
Catecholamines and associated metabolites were analysed in plasma to assess the impact of MAO 163 
activity on associated substrates.  164 
Materials 165 
Formic acid (Riedel-de Haën), ammonium formate and acetic anhydride (Fluka), were purchased from 166 
Sigma Aldrich (Auckland, New Zealand). Di-sodium tetraborate (BDH) was purchased from Global 167 
Science (Auckland, New Zealand).  Optima LC/MS grade acetonitrile (Fisher Scientific) was purchased 168 
from ThermoFisher (Auckland, New Zealand). Water was of Milli-Q grade. Analytical standards, 169 
dopamine, normetadrenaline, noradrenaline, adrenaline, 3,4-dihydroxyphenylglycol (DHPG), 170 
serotonin, 3,4-dihydroxyphenylacetic acid (DOPAC), L-3,4-dihydroxyphenyl alanine (DOPA) and 171 
homovanillic acid (HMV) were purchased from Sigma-Aldrich and phenylethylamine (PEA) from Acros 172 
Organics (Geel, Belgium). Deuterated acetic anhydride [d6] was purchased from Sigma-Aldrich and 173 
deuterated dopamine [d4] and DOPA [d3] from CDN Isotopes (Quebec, Canada).  174 
 175 
 176 
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Standard Preparation 177 
Individual stock standards (1000 mg/ml) (PEA, dopamine, serotonin, normetadrenaline, 178 
noradrenaline, adrenaline, DHPG, DOPAC, DOPA and HMV) were prepared in 0.1 % formic acidaq, and 179 
used to create a mixed catecholamine standard of all compounds (10 mg/ml). Two separate labelled 180 
internal standards for spiking and recovery were also prepared (IS1) DOPA [d3] 10 mg/ml and (IS2) 181 
dopamine [d4] 10 mg/ml. One hundred millilitres of each of these standards was derivatised 182 
separately, as described for the samples, to prepare a derivatised mixed standard, and two derivatised 183 
internal standards (IS1 and IS2). The derivatised mixed standard was used to prepare calibration 184 
standards in the range 0.02 ng/ml to 5 ng/ml. 185 
To facilitate quantitation and to correct for matrix effects during analysis, labelled internal standards 186 
for each analyte were prepared (d-IS) by derivatising 100 ml of the mixed catecholamine standard (10 187 
mg/ml), as described for the samples, with the exception that deuterated acetic anhydride [d6] was 188 
used in place of unlabelled acetic anhydride. 189 
All calibration standards were spiked with 10 ml of the derivatised internal standards [(IS1) DOPA [d3] 190 
100 ng/ml and (IS2) dopamine [d4] 100 ng/ml; final concentration 1 ng/ml] and 100 µl of the 191 
derivatised labelled internal standard catecholamine mixture [(d-IS) 10 ng/ml; final concentration 1 192 
ng/ml] and prepared at a final volume of 1 ml. 193 
Sample Preparation 194 
Plasma samples were treated to remove proteins and derivatised in two stages to acetylate alcohol 195 
and amine functional groups prior to LC-MS analysis. A double derivatisation was found to be 196 
necessary to acetylate the less reactive alkyl hydroxyl groups. Briefly, each plasma sample (200 µl) was 197 
added to a 1.5 ml microtube already containing 600 µl cold acetonitrile, 100 µl acetic anhydride and 198 
10 µl 100 ng/ml DOPA d3 [(IS1); final concentration 1 ng/ml] and mixed well. Samples were chilled at 199 
-80 oC for 15 minutes then centrifuged at 16100 g for 15 min, and the filtrate transferred to a 15 ml 200 
screw capped glass culture tube. A further 200 µl acetonitrile was added to each microtube, mixed, 201 
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centrifuged at 16100 g for 15 min and the filtrate combined with the original filtrate. To each 202 
combined sample filtrate 10 µl 100 ng/mL dopamine d4 [(IS2); final concentration 1 ng/ml] was added 203 
and the samples derivatised by the addition of 200 µl 100 mM borate buffer (3.81g in 100 ml of water) 204 
and 100 µl acetic anhydride and microwaved at 30 % power for 15 minutes. Samples were then 205 
evaporated to just dry with nitrogen at 50 oC. Samples were re-derivatised; 100 µl acetonitrile, and 206 
100 µl acetic anhydride and microwaved at 30 % power for 15 minutes. Finally, to each sample 100 µl 207 
of the derivatised labelled internal standard catecholamine mixture [(d-IS) 10 ng/ml; final 208 
concentration 1 ng/mL] was added, and the samples made up to 1 ml with water and transferred to 209 
an autosampler vial ready for analysis. 210 
 211 
LC-MS Analysis 212 
Analysis of catecholamines was performed using an AB Sciex Qtrap 5500 equipped with a Turbo V 213 
electrospray source (ESI) (AB Sciex, Foster City, California, USA), coupled to a Dionex UltiMate 3000 214 
HPLC system, which consisted of two UltiMate 3000 RS pumps, an UltiMate 3000 RS autosampler and 215 
an UltiMate 3000 RS column compartment (Dionex, Olten, Switzerland) and controlled with Analyst 216 
1.5.2 software. A 150 by 2.1 mm Atlantis® T3 analytical column, (3 µm particle size; Waters Corp., 217 
Milford, MA, USA) maintained at 50 oC was used. Solvents were (A) MilliQ water +0.03 % ammonium 218 
formate + 0.1 % formic acid and (B) acetonitrile + 0.1 % formic acid and the flow rate was 0.6 ml/min. 219 
The initial mobile phase, 100 % A, was ramped linearly to 70 % A at 12 min, 30 % A at 15 min, and 0 % 220 
A at 15.5 min and held for 4 min before resetting to the original conditions. Sample injection volume 221 
was 50 µl.  222 
The ESI conditions were: gas 1, nitrogen (40 psi); gas 2, nitrogen (50 psi); ion spray voltage, 2500 V; 223 
ion source temperature, 700 oC; curtain gas, nitrogen (50 psi). LC/MS data was acquired in the positive 224 
mode using the most intense selected reaction monitoring (SRM) transition for each compound. In 225 
some cases the ammonium adduct was the most abundant ion observed for Q1. A detailed description 226 
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of analyte specific MS parameters is given in table 4 . Quantitation was performed using the internal 227 
standard ratio method using MultiQuant software.  228 
Table 4 near here 229 
Glucose and lactate analysis 230 
Twenty microlitres of whole blood were collected from the inlaying cannula in an end-to-end capillary 231 
(EKF Diagnostics, Surrey, UK) and immediately transferred into an EKF safe-lock cup prefilled with 1 232 
ml of haemolysis solution. The whole blood in haemolysis solution was then analysed using a Biosen 233 
C_line analyser (EKF Diagnostics, Surrey, UK) for glucose (mmol/L) and lactate (mmol/L) within 30 234 
minutes of collection. The manufacturer reports that the Biosen C_line analyser has a coefficient of 235 
variance of 1.5 %. 236 
Procedures 237 
Participants were required to attend the laboratory a total of three times. The first was a screening 238 
visit to ensure eligibility, the second and third were study visits. On all study day visits, participants 239 
arrived in the laboratory at 8 am and confirmed that they had fasted for 12 hours prior and were in 240 
good health. An inlaying cannula was then inserted into the participants left median cubital vein by a 241 
qualified phlebotomist. Fifteen millilitres of blood were then drawn from the cannula using a 5 ml 242 
vacutainer containing EDTA and a 10 ml vacutainer containing LH. Depending upon randomised 243 
treatment allocation, the participant then consumed either ‘Blackadder’ juice or the matched control. 244 
Drinks were presented to participants chilled in a sealed opaque bottle and they were given 5 minutes 245 
to consume the drink through a straw. A further 15 ml of blood was then removed via the cannula; at; 246 
15, 30, 45 60, 100, 120, 150, 180 and 240 minutes post consumption. Participants were then free to 247 
leave. Participants were required to attend a 24 hour follow up visit where 15 ml of blood was 248 
obtained via venepuncture. Diet was controlled (nil by mouth other than water) during the 4 hour 249 
period after consumption of the treatments. There was no standardisation of food intake across visits 250 
during 4-24 hours. Participants were however asked to consume no purple coloured berries. A 251 
graphical representation of the study design can be seen in Figure 1. 252 
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FIGURE 1 NEAR HERE 253 
 254 
Statistical analysis  255 
Data from baseline through to 240 minutes post-consumption were analysed to assess the Cmax and 256 
Tmax of the biological parameters up to four hours post dose. Twenty-four hour follow-up data was 257 
analysed to assess if values had returned to baseline 24 hours post-dose. 258 
For all blood parameters an estimation of the area under the curve (AUC) was calculated using 259 
the incremental trapezoidal method. AUC was calculated incrementally from time point; 0 to 15, 15 260 
to 30, 30 to 45, 45 to 60, 60 to 100, 100 to 120, 120 to 150, 150 to 180 and 180 to 240 minutes using 261 
“unchanged” raw data (iAUC). Increments were then summed to give an area under the curve from 262 
time point zero, to the last observed study day concentration at 240 minutes post consumption (AUCo-263 
t).  264 
Treatment effects were analysed with linear mixed models (LMM) including the terms 265 
treatment, assessment, treatment x assessment as fixed effects for AUC. Pairwise comparisons 266 
corrected for least squares difference, were conducted on all outcomes with a p value <0.05 from the 267 
initial mixed model analysis to ascertain any differences between treatments for the whole session 268 
and at specific epochs. Twenty-four hour assessments were analysed on “raw” values using repeated 269 
measures LMM including the terms treatment x assessment (baseline and 24h) as fixed effects. All 270 
data were tabulated using Microsoft Excel 2013 and analyses were conducted with IBM SPSS Statistics 271 
22. 272 
 273 
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Results 274 
Analysis of baseline data revealed there were no significant pre-dose differences between treatments 275 
on any measures. Area under the curve data can be found in Table 5. Twenty-four hour post-data are 276 
presented in Table 6. Outcomes that elicited a significant effect in the initial LMM are outlined below. 277 
Platelet MAO-B activity 278 
Analysis of AUCo-t data revealed a significant effect of treatment [F(1,12.43)=67.2, p<0.001]. This was 279 
observed to be due to a significant reduction in AUC platelet MAO-B activity after consumption of 280 
‘Blackadder’ when compared to control. Analysis of iAUC data revealed a significant 281 
treatment*increment interaction [F(8,14.77)=13.00, p<0.001]. Pairwise analysis of the increments 282 
revealed significantly lower iAUC at, 15–30 (p<0.001), 30–45 (p=0.002), 45–60 (p<0.001), 60–100 283 
(p=0.001), 100–120 (p<0.001), 120–150 (p<0.001), 150–180 (p<0.001) and 180–240 minutes (p=0.001) 284 
following ‘Blackadder’ when compared to control. There were no significant effects of treatment at 285 
the 24 hour time point. Please see Figure 2a. 286 
Prolactin 287 
Analysis of AUCo-t data revealed a significant effect of treatment [F(1,13)=6.24, p=0.027]. This was 288 
observed to be due to a significant reduction in prolactin after consumption of ‘Blackadder’ when 289 
compared to control. Analysis of iAUC data revealed a significant treatment*increment interaction 290 
[F(8,24)=3.12, p0.012]. Pairwise analysis of the increments revealed significantly or trend to 291 
significantly lower iAUC at 45-60 (p=0.083), 60-100 (p=0.009), 100–120 (p<0.03), 120–150 (p=0.012), 292 
150–180 and (p=0.05) following ‘Blackadder’ when compared to control. There were no significant 293 
effects of treatment at the 24 hour time point. Please see Figure 2b. 294 
 295 
FIGURE 2 NEAR HERE 296 
TABLE 5 NEAR HERE 297 
TABLE 6 NEAR HERE 298 
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Discussion 299 
Results from this randomised, placebo-controlled, double blind, counterbalanced cross-over trial 300 
demonstrate a fast and absolute inhibition of blood platelet MAO-B and a significant reduction in 301 
plasma prolactin induced by the consumption of the New Zealand ‘Blackadder’ blackcurrant juice 302 
when compared to a placebo control. 303 
The current study illustrates a sustained significant reduction in peripheral platelet MAO-B 304 
activity of ~100 % by consuming ‘Blackadder’ blackcurrant when compared to control. This reduction 305 
began within 15 minutes of consumption, during the first post-dose epoch measured, and continued 306 
to be significantly reduced through to four hours post dose, that being the last measurement on the 307 
day of treatment. Platelet MAO-B activity had returned close to the pre-dose baseline level 24 hours 308 
post dose. Due to the extremely rapid inhibition of the platelet MAO-B enzyme, it is not possible to 309 
calculate a time to maximal inhibition. It would therefore be useful if future studies were conducted 310 
using several doses and shorter initial blood collection epochs. The profile of MAO-B inhibition of 311 
‘Blackadder’ juice bears a notable similarity, to pharmaceutical reversible MAO-B specific inhibitors 312 
such as lazabemide, which have shown a rapid inhibition of MAO-B in platelets of >90 % at 30 minutes 313 
post dose, with maximal inhibition subsiding 16 hours post dose and full restoration of enzyme activity 314 
returning 48 hours post dose following a 100 mg dose of lazabemide [22]. The active compound or 315 
compounds driving the inhibition in the present study are currently not known. Data in the literature 316 
outline an inhibition of MAO-B by anthocyanins in vitro [23]; however, this study used levels 1000 317 
times higher than quantified in plasma after oral consumption [7]. In addition maximal plasma 318 
concentrations of anthocyanins do not occur until one to two hours post oral consumption [24], 319 
making it unlikely that they explain the effects seen at 15 minutes in the current study. Coupled with 320 
the inability of a blackcurrant anthocyanin-enriched extract (DelcyanTM) to inhibit platelet MAO-B in 321 
our previous publication [7], these data suggest that anthocyanins are not likely to be the compound 322 
driving MAO inhibition in vivo. However, this does not rule out a synergy between anthocyanins and 323 
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lower molecular weight phenolic components such as phenolic acids. Further research needs to be 324 
conducted to attempt to identify the components responsible for the observed MAO inhibition. 325 
Plasma levels of 3,4-dihydroxyphenylglycol (DHPG) levels were not significantly impacted after 326 
the consumption of ‘Blackadder’ juice.  However, the pattern observed highlights that DHPG was 327 
reduced by ~30 % when compared to baseline at 100 minutes before rapidly returning to baseline by 328 
3 hours post dose. As a proxy for MAO-A activity [20] these data indicate an inhibition of the MAO-A 329 
enzyme in the periphery. AUC analysis showed no significant differences in normetadrenaline up to 4 330 
hours after consumption of `Blackadder’ blackcurrant. However, exploration of the data indicates 331 
approximately 100 % increase in normetadrenaline when compared to control at 150 minutes, which 332 
indicates an increased breakdown of adrenaline via catechol- methyl transferase (COMT) and is in line 333 
with our previous observation [7] Analysis of data 24 hours post consumption also shows a significant 334 
increase in normetadrenaline, indicating circulating normetadrenaline is still above baseline 24h post 335 
dose. There were no other significant changes in measured catecholamines or associated metabolites 336 
between treatment groups. 337 
As anticipated, peripheral prolactin was significantly reduced after consumption of 338 
‘Blackadder’ juice when compared to placebo, confirming our previously reported non-significant 339 
reductions. Reductions were seen as early as 30 minutes post consumption, with significantly lower 340 
area under the curve increments beginning 45 minutes post dose and continuing until the last 341 
measured concentration at 240 minutes post dose. The maximal reduction appeared at the 120 342 
minute epoch with a reduction of 61 %. These findings are consistent with inhibition of prolactin 343 
secretion by the central D2 receptor agonist bromocriptine, 12 mg of which reduces peripheral 344 
prolactin by ~ 60 % two hours post dose [25]. Since dopamine receptor agonists have been show to 345 
inhibit peripheral prolactin secretion [25, 27], these data indicate the possibility of a centrally active 346 
inhibition of MAO-B and an increase in central dopamine levels after ingestion of the ‘Blackadder’ 347 
juice in healthy young men. Although it must be noted that there are no reports in the literature of 348 
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direct interactions between constituents found in blackcurrants and the suppression of prolactin 349 
excretion from the pituitary gland, this mode of action cannot be ruled out. 350 
With regards to blood glucose modulation, post prandial profiles were not statistically 351 
different. However, examination of the data showed that consumption of ‘Blackadder’ juice reduced 352 
the post-prandial peak of blood glucose, and delayed the peak by 15 minutes when compared to the 353 
control beverage(see figure 2c). Although not significant, a modulation of blood glucose occurs until 354 
100 minutes post consumption of ‘Blackadder’ juice when compared to the sugar matched control 355 
with lower plasma levels until ~35 minutes post dose. Higher blood glucose levels are seen until 100 356 
minutes post dose, after which glucose levels return to a level similar to control and remain that way 357 
until the last measured time point at 240 minutes post dose. Blood glucose followed a similar pattern 358 
of modulation described by Törrönen et al., [28] and Wilson et al., [29], with reduced levels from the 359 
first post-dose measurement at 15 minutes until one hour post dose. In the current study, glucose 360 
findings are coupled with a non-significant reduction in post-prandial lactate 15 minutes post 361 
consumption of ‘Blackadder’ blackcurrant when compared to control. As lactate is a by-product of 362 
glucose metabolism, this further supports the hypothesis that the pattern of glucose modulation was 363 
a result of moderately slowed glucose absorption rather than an increase in metabolism. Although 364 
samples in the current study were taken at regular time points via cannulation, it must be noted that 365 
the infrequent samples make the assumption that the modulation in blood glucose is linear between 366 
each sample. It would be beneficial to use such methods as interstitial continuous glucose monitoring 367 
as used by Dye et al., (2010) to allow for a full “real time” profile of the effects of ‘Blackadder’ 368 
blackcurrant upon blood glucose to be monitored. 369 
Monoamine oxidase inhibitors have been highlighted as a tool to attenuate age related 370 
decline of behavioural performance and decrease susceptibility to senile depression, Parkinson’s 371 
disease and Alzheimer’s disease” [8]. Data from this current trial provide invaluable pharmacodynamic 372 
information pertaining to the impact of ‘Blackadder’ blackcurrant juice upon platelet MAO-B activity 373 
and peripheral prolactin. The findings suggest a reversible non-selective inhibition of the MAO 374 
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enzymes by ‘Blackadder’ juice, although a somewhat greater affinity to MAO-B is indicated. These 375 
changes in MAO inhibition were evident without a measurable accumulation of monoamines in the 376 
periphery. Future research should utilise blackcurrant’s reversible MAO-inhibiting properties and 377 
assess its impact upon cognitive functioning in a population at risk of age-related cognitive decline. 378 
 379 
 380 
  381 
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Table 2 Phytochemical constituents of ‘Blackadder’ blackcurrant juice 
(mg/100 ml of raw juice and dosing range supplemented). 
Compound 
Quantity 
(mg/100 
ml) 
Dose range 
mg 
3-Caffeoylquinic acid 6 5.88- 6.97 
Caffeoylhexose 2.5 2.50- 2.97 
3-p-Coumaroylquinic acid 5.7 5.63- 6.68 
Epigallocatechin 4.9 4.88- 5.79 
Delphinidin 3-O-glucoside 47.7 47.13- 55.92 
Delphinidin 3-O-rutinoside 184.6 182.38- 216.42 
Cyanidin 3-O-glucoside 20.6 20.38- 24.18 
Cyanidin 3-O-rutinoside 206.5 204.00- 242.08 
Petunidin 3-O-rutinoside 3.5 3.50- 4.15 
Pelargonidin 3-O-rutinoside 3.7 3.63- 4.30 
Peonidin 3-O-rutinoside 5.4 5.38- 6.38 
Myricetin 3-O-rutinoside 15.3 15.13- 17.95 
Myricetin 3-O-glucoside 2.2 2.13- 2.52 
Quercetin 3-O-rutinoside 3.6 3.50- 4.15 
Quercetin 3-O-glucoside 2 2.00- 2.37 
Quercetin 3-O-pentoside 1.7 1.63- 1.93 
Myricetin 2.2 2.13- 2.52 
Total anthocyanins 
Total polyphenols 
474 
636 
465–555 
624–744 
469 
Table 1 Mean participant characteristics   
Measure 
Average 
measurement 
SD Range 
Age (years) 25.3 4.7 20–35 
Height (m) 1.81 0.07 1.7–1.95 
Mass (kg) 82.31 4.73 75–89 
BMI (kg/m2) 24.99 2.01 21–27 
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Table 3 Anthocyanins and other phenolic compounds in each of the treatment conditions (mg per kilo of body weight, average dose given (mg) and dose range (mg))  
Treatment Anthocyani
ns (mg/kg) 
Anthocyanin average 
dose (mg) 
Anthocyanin 
dose 
range (mg) 
Other polyphenols 
(mg/kg) 
Other polyphenols average 
dose (mg) 
Other polyphenols dose 
range (mg) 
Total polyphenols 
(mg/kg) 
Total polyphenols average 
dose (mg) 
Total polyphenols dose 
range (mg) 
Control 0 0 0 0 0 0 0 0 0 
‘Blackadder’ 6.21 511 465–555 2.11 173 158–188 8.33 685 624–744 
 
  Table 4: MRM Transitions used for catecholamines and their isotopically labelled internal standard analogues 
Q1 Q3 Time Name DP EP CE CXP 
344 197 8.65 DOPA d3 (IS1) 70 10 35 16 
353 201 8.58 DOPA d3 [d9] 70 10 35 16 
341 194 8.67 DOPA 70 10 35 16 
350 198 8.60 DOPA [d9] 70 10 35 16 
164 105 8.98 PEA  30 10 25 10 
167 105 8.95 PEA [d3] 30 10 25 10 
261 160 9.75 Serotonin  10 5 25 1 
267 161 9.70 Serotonin [d6] 10 5 25 1 
284 141 9.81 Dopamine [d4] (IS2) 70 10 37 15 
293 143 9.74 Dopamine [d4] [d9] 70 10 37 15 
280 137 9.85 Dopamine  70 6 35 15 
289 139 9.78 Dopamine [d9] 70 6 35 15 
242 137 9.89 HMV  50 10 30 16 
245 137 9.85 HMV [d3] 50 10 30 16 
270 165 9.93 DOPAC 50 10 15 15 
276 168 9.87 DOPAC [d6] 50 10 15 15 
250 166 10.58 Normetadrenaline 50 9 25 15 
256 168 10.50 Normetadrenaline [d9] 50 9 25 15 
355 194 10.61 Noradrenalin 10 10 30 1 
367 199 10.51 Noradenalin [d12] 10 10 30 1 
292 250 12.19 Adrenalin  170 10 20 1 
301 257 12.09 Adrenalin [d12] 170 10 20 1 
356. 237 14.09 DHPG  90 13 20 20 
368 244 14.05 DHPG [d12] 90 13 20 20 
Declustering potential (DP), entrance potential (EP), collision energy (CE), collision cell exit potential (CXP) retention time (time),  
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parent ion (Q1) and product ion (Q3). Table 5 Incremental and total AUC data for the control and ‘Blackadder’ blackcurrant (Ribes nigrum) for blood outcomes MAO-B prolactin, glucose and lactate and linear mixed model outcomes 
Outcome Treatment N 
0 to 15  
minutes 
15 to 30  
minutes 
30 to 45  
minutes 
45 to 60 
minutes 
60 to 100  
minutes 
100 to 120  
minutes  
120 to 150  
minutes  
150 to 180 
minutes  
180 to 240 
 minutes  
Total AUC 
Effect of 
treatment 
Treatment* 
increment 
interaction Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
MAO-B 
(ng/ml) 
Control 
7 
17305 5835 16850 6095 14774 4600 15052 4066 34649 9936 40411 17103 43400 18830 44437 17936 91500 35631 318379 112471 F=67 
p<0.001 
F=13 p<0.001* 
‘Blackadder’ 12758 8394 1375 2390 63 166 0 0 0 0 0 0 1195 2317 2339 2774 8834 9370 26564 19634 
Prolactin 
(ng/ml) 
Control 
8 
4232 980 3665 793 3391 795 3208 861 6349 1872 6318 1997 5820 2172 5465 2209 11023 4879 49472 14764 F=6.24 
p<0.001 
F=3.12 p=0.012 
‘Blackadder’ 4155 927 3523 834 3074 799 2739 744 4514 1127 3733 1014 3557 1174 3753 1399 8286 3928 37333 11362 
Glucose 
mmol/ml) 
Control 
8 
76.20 14.79 87.06 21.78 73.67 20.82 57.57 15.90 108.13 20.54 113.64 12.48 118.58 9.23 122.21 8.01 249.45 8.52 894.68 450.71 F=0.12 
=0.91 
F=2.08 p=0.01* 
‘Blackadder’ 69.39 9.39 77.64 15.16 75.34 16.37 64.04 18.52 112.33 21.81 113.44 12.88 118.95 9.64 123.60 11.03 248.44 15.99 891.71 451.11 
Lactate 
(ng/ml) 
Control 
8 
13.65 5.16 19.48 8.54 21.83 7.30 20.06 6.17 30.88 10.13 21.88 7.42 20.14 5.92 21.58 5.86 43.84 12.31 213.33 56.17 F=1.55 
>0.25 
F=1.58 =0.15 
‘Blackadder’ 14.31 5.30 16.76 5.88 20.80 7.09 22.35 6.15 36.58 7.00 27.84 6.20 23.46 6.76 22.14 6.32 42.21 15.87 226.45 49.07 
Noradrenalin
e (ng/ml) 
Control 
8 
10.13 2.31 10.55 3.61 10.22 4.75 11.68 6.77 24.56 11.75 23.04 9.03 22.29 8.69 20.88 7.37 39.13 11.43 172.49 54.90 F=0.97 
P=0.33 
F=0.74.47 P=0.65 
‘Blackadder’ 7.03 1.54 7.56 2.16 8.15 3.12 9.53 3.68 19.28 7.45 17.99 8.64 19.31 9.28 21.38 6.60 42.02 12.00 152.25 49.77 
Normetadren
aline (ng/ml) 
Control 
8 
6.97 2.60 7.72 4.22 7.39 5.25 8.95 7.48 17.48 14.29 14.04 10.93 14.22 8.98 11.99 4.22 21.64 5.69 110.39 52.62 F=0.01 
P=0.92 
F=1.03.47 P=0.42 
‘Blackadder’ 4.99 3.32 6.02 3.85 6.25 3.69 6.99 3.47 14.80 7.96 13.13 7.35 13.32 6.30 14.47 5.41 27.94 8.06 107.92 38.80 
Serotonin 
(ng/ml) 
Control 
8 
394.78 248.33 319.90 226.52 258.87 161.54 232.74 140.4 978.90 572.89 1481.13 944.93 1254.10 746.35 1071.53 728.45 1322.57 861.70 7314.52 3846.21 F=0.17 
P=0.68 
F=0.40 P=0.90 
‘Blackadder’ 438.13 361.61 333.94 239.81 248.67 141.85 215.24 82.75 752.41 417.04 1110.16 884.23 1056.18 722.17 919.20 598.86 1455.84 818.52 6529.76 3678.81 
Dopamine 
(ng/ml) 
Control 
8 
5.93 6.17 5.51 5.43 4.41 5.03 4.20 4.77 7.74 6.94 6.91 6.40 6.51 5.32 5.30 3.60 9.11 7.05 55.62 45.00 F=1.56 
P=0.22 
F=0.69 P=0.69 
‘Blackadder’ 2.60 1.58 2.64 1.38 2.16 0.94 2.53 1.31 5.23 3.03 4.18 2.33 4.47 1.99 5.25 3.23 10.48 6.25 39.54 15.87 
DHPG (ng/ml) 
Control 
8 
18.46 5.01 18.68 6.55 17.99 6.42 20.96 6.54 38.04 13.79 34.11 8.32 37.75 9.90 40.85 12.96 84.81 28.62 310.29 56.80 F=1.93 
P=0.17 
F=0.33 P=0.94 
‘Blackadder’ 16.55 4.72 15.91 5.61 14.28 5.93 14.71 7.55 28.61 21.90 27.35 26.17 31.12 20.70 34.98 13.63 73.61 20.14 255.27 111.54 
DOPAC 
(ng/ml) 
Control 
8 
54.47 21.98 54.23 20.11 46.70 16.57 47.26 15.63 99.98 38.35 94.17 36.94 95.50 31.06 92.04 21.23 176.83 41.90 761.18 213.20 F=0.59 
P=0.44 
F=0.97 P=0.47 
‘Blackadder’ 57.97 23.21 52.02 22.85 48.05 21.14 47.68 16.36 84.71 25.72 73.58 30.39 78.54 37.11 88.00 40.72 178.93 68.06 709.47 269.69 
DOPA (ng/ml) 
Control 
8 
22.49 8.99 23.00 8.83 21.87 8.29 20.56 9.21 43.89 16.51 45.89 12.80 51.71 17.84 52.54 22.08 110.57 44.57 391.29 101.25 F=1.43 
P=0.24 
F=0.71 P0.67 
‘Blackadder’ 23.94 9.52 20.72 6.69 20.14 7.84 22.18 9.49 44.02 11.13 38.45 8.68 42.45 9.52 45.59 17.13 82.63 36.46 337.12 91.05 
PEA (ng/ml) 
Control 
8 
0.75 0.44 0.73 0.32 0.65 0.35 0.64 0.33 1.36 0.55 1.44 0.76 1.36 0.80 1.18 0.62 2.87 1.24 10.99 4.99 F=0.55 
P=0.46 
F=1.66 P=0.14 
‘Blackadder’ 0.68 0.29 0.75 0.34 0.71 0.35 0.86 0.40 1.91 1.00 1.43 0.76 1.38 0.49 1.56 0.53 2.76 0.76 11.89 4.03 
HMV (ng/ml) 
Control 
8 
183.25 52.42 182.55 43.60 184.58 48.48 176.00 51.91 333.74 72.15 296.84 55.03 287.49 47.86 279.83 46.30 544.37 78.47 2461.11 436.17 F=0.21 
P=0.64 
F=0.65 P=0.72 
‘Blackadder’ 212.44 87.91 202.63 87.52 183.79 76.57 179.82 50.86 326.59 81.82 281.32 77.11 256.87 95.35 256.36 56.27 483.77 87.04 2367.79 676.80 
Monoamine oxidase-B (MAO-B); Homovanillic acid (HVA); 3,4-Dihydroxyphenylacetic (DOPAC); Dihydroxyphenylalanine (DOPA); phenylethylamine (PEA); 3,5-Dihydroxyphenylglycine (DHPG 
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Table 6 Mean change from baseline scores, standard deviations and LMM outcomes for all 24 hour parameters  
Measure Treatment N 
Baseline 24h Treatment* 
repetition 
effect 
Mean SD Mean SD 
MAO-B Control 
7 
1074.40 376.60 1739.99 681.07 
F=1.99 p=0.171  
(nmol H2O2) ‘Blackadder’ 1526.02 1095.21 1417.86 542.26 
Prolactin Control 
8 
308.32 86.65 332.67 120.66 
F=0.72 p=0.79  
(mIU/L) ‘Blackadder’ 296.46 69.68 301.01 122.47 
Glucose Control 
8 
4.26 0.47 4.50 0.35 
F=0.17 p=0.68 
(mmol/L) ‘Blackadder’ 4.23 0.44 4.34 0.60 
Lactate Control 
8 
0.72 0.23 1.01 0.44 
F=0.335 p=0.56 
(mmol/L) ‘Blackadder’ 0.93 0.37 0.66 0.30 
HMV  
(ng/ml) 
Control 
8 
12.45 4.44 12.86 7.46 
F=0.86 p=0.36 
‘Blackadder’ 14.20 5.34 10.85 4.51 
DOPAC  
(ng/ml) 
Control 
8 
3.55 1.51 4.64 4.82 
F= 0.85 p=0.36 
`Blackadder’ 3.90 1.61 3.22 0.94 
Noradrenaline  
(ng/ml) 
Control 
7 
0.65 0.14 0.50 0.21 
F=6.70 p=0.16 
‘Blackadder’ 0.40 0.12 0.54 0.13 
Normetadrenaline Control 
8 
0.46 0.14 0.37 0.17 
F=5.28 p=0.03* 
(ng/ml) ‘Blackadder’ 0.27 0.17 0.52 0.32 
Serotonin  Control 
7 
27.24 17.55 17.49 23.60 
F=0.14 p=0.71 
(ng/ml) ‘Blackadder’ 30.63 25.17 15.28 13.14 
Dopamine  Control 
8 
0.41 0.44 0.22 0.17 
F=2.97 P=0.96 
(ng/ml) ‘Blackadder’ 0.14 0.10 0.51 0.77 
DOPA Control 
7 
1.39 0.55 1.52 0.76 
F=1.16 p=0.29 
(ng/ml) ‘Blackadder’ 1.73 0.69 1.31 0.83 
PEA Control 
7 
0.05 0.03 0.05 0.03 
F=0.65 p=0.42 
(ng/ml) ‘Blackadder’ 0.04 0.03 0.06 0.04 
DHGP Control 
7 
1.37 0.31 1.22 0.66 
F=2.68 P=0.11 
(ng/L) ‘Blackadder’ 0.95 0.15 1.28 0.34 
Monoamine oxidase-B (MAO-B); Homovanillic acid (HVA); 3,4-Dihydroxyphenylacetic (DOPAC); Dihydroxyphenylalanine 
(DOPA); phenylethylamine (PEA); 3,5-Dihydroxyphenylglycine (DHPG) 
 
 
Supplementary table 1. Raw catecholamine data 
Outcome Treatment 
Baseline 15 minutes  30 minutes 45 minutes 60 minutes 90 minutes 120 minutes 150 minutes 180 minutes 240 minutes 24h 
Score SD Score SD Score SD Score SD Score SD Score SD Score SD Score SD Score SD Score SD Score SD 
DHPG (ng/ml) Control 1.37 0.31 1.24 0.50 1.34 0.60 1.30 0.29 1.42 0.63 1.23 0.61 1.41 0.75 1.30 0.52 1.42 0.43 1.32 0.47 1.22 0.66 
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‘Blackadder’ 0.95 0.15 1.11 0.26 1.05 0.41 0.90 0.25 0.86 0.26 0.67 0.30 0.89 0.48 1.07 0.44 1.27 0.46 1.27 0.38 1.28 0.34 
DOPAC (ng/ml) 
Control 3.55 1.51 3.71 1.46 3.52 1.27 3.09 0.91 3.60 1.50 3.07 1.15 3.21 1.42 3.16 0.80 2.98 0.68 2.92 0.82 4.64 4.82 
‘Blackadder’ 3.90 1.61 3.83 1.49 3.55 1.42 3.30 1.43 3.06 0.85 2.59 0.90 2.65 0.87 2.92 1.32 2.95 1.41 3.02 0.87 3.22 0.94 
DOPA (ng/ml) 
Control 1.39 0.55 1.61 0.66 1.46 0.66 1.48 0.82 1.45 0.94 1.48 0.31 1.58 0.69 1.87 0.66 1.63 0.89 2.05 0.71 1.52 0.76 
‘Blackadder’ 1.73 0.69 1.46 0.64 1.33 0.60 1.52 0.90 1.43 0.65 1.50 0.48 1.22 0.32 1.64 0.44 1.40 0.79 1.35 0.66 1.31 0.83 
PEA (ng/ml) 
Control 0.05 0.03 0.05 0.03 0.05 0.03 0.04 0.02 0.05 0.02 0.05 0.03 0.05 0.02 0.04 0.03 0.05 0.03 0.05 0.02 0.05 0.03 
‘Blackadder’ 0.04 0.03 0.05 0.02 0.05 0.03 0.05 0.02 0.06 0.04 0.06 0.03 0.05 0.03 0.05 0.01 0.05 0.02 0.05 0.02 0.06 0.04 
HMV acid  
(ng/ml) 
Control 12.45 4.44 11.98 2.85 12.36 3.38 12.85 3.10 12.22 2.93 10.03 2.05 9.76 2.04 9.40 1.68 9.25 1.69 8.89 1.26 12.86 7.46 
Blackadder 14.20 5.34 14.12 6.44 13.93 5.18 12.32 3.99 11.66 3.22 10.12 2.47 9.07 2.86 9.18 2.63 7.91 1.57 8.22 1.70 10.85 4.51 
Noradrenaline 
(ng/ml) 
Control 0.46 0.14 0.56 0.40 0.77 0.81 0.54 0.44 0.39 0.14 0.37 0.17 0.46 0.14 0.56 0.40 0.77 0.81 0.54 0.44 0.39 0.14 
‘Blackadder’ 0.27 0.17 0.47 0.33 0.51 0.34 0.45 0.27 0.47 0.17 0.52 0.32 0.27 0.17 0.47 0.33 0.51 0.34 0.45 0.27 0.47 0.17 
Normetadrenaline 
(ng/ml) 
Control 0.46 0.14 0.47 0.24 0.56 0.40 0.48 0.34 0.77 0.81 0.40 0.31 0.54 0.44 0.41 0.23 0.39 0.14 0.33 0.10 0.37 0.17 
‘Blackadder’ 0.27 0.17 0.40 0.29 0.47 0.33 0.43 0.22 0.51 0.34 0.48 0.29 0.45 0.27 0.49 0.23 0.47 0.17 0.46 0.13 0.52 0.32 
Serotonin (ng/ml) 
Control 27.24 17.55 25.40 19.22 17.25 13.55 19.73 12.79 13.77 8.39 51.49 33.79 47.25 30.43 36.36 23.54 35.08 27.24 9.01 4.17 17.49 23.60 
‘Blackadder’ 30.63 25.17 27.78 23.63 19.13 16.93 16.41 8.19 12.28 8.20 37.88 29.80 41.30 29.58 34.28 22.44 27.00 20.49 21.53 16.56 15.28 13.14 
Dopamine (ng/ml) 
Control 0.41 0.44 0.38 0.40 0.36 0.35 0.27 0.35 0.33 0.32 0.19 0.18 0.27 0.26 0.16 0.11 0.19 0.15 0.11 0.09 0.22 0.17 
‘Blackadder’ 0.14 0.10 0.21 0.14 0.17 0.07 0.14 0.08 0.20 0.12 0.15 0.11 0.14 0.06 0.17 0.10 0.18 0.15 0.17 0.08 0.51 0.77 
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Figure 1 Study day running order. Scale depicts minutes post supplementation of the study intervention. CRF= case report form. 
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Figure 2. “Unchanged” raw values for platelet MAO-B activity (a) and 
blood plasma prolactin levels (b) and blood glucose levels (c) and plasma 3,4-dihydroxyphenylglycol (DHPG) (d) t(p<0.1). Shaded areas depict increments where p<0.05 in the 
treatment*increment pairwise comparisons. Open circles depict control and closed circles depict 'Blackadder' juice. 
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